DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 20, 2005; DOI: 10.1124/dmd.105.004325


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.004325v1
33/7/873    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Locuson, C.
Right arrow Articles by Wahlstrom, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locuson, C.
Right arrow Articles by Wahlstrom, J.


Received for publication February 17, 2005.
Revised April 13, 2005.
Accepted for publication April 14, 2005.

3D-QSAR analysis of CYPs: Effect of incorporating higher affinity ligands and potential new applications

Charles Locuson 1* Jan Wahlstrom 2

1 University of Minnesota 2 Pfizer St. Louis

* Address correspondence to: E-mail: locus003{at}umn.edu

Abstract

Recently two new classes of reversible inhibitors, the benzbromarones (BZBR) and the N-3 substituted phenobarbitals (PB), were used to study the active site characteristics of CYPs 2C9 and 2C19, respectively. Since these ligands are some of the first CYP2C ligands to extend into the low nanomolar Ki range (Ki < 100 nM), they were subjected to three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Given that BZBR or the PB ligands bind very tightly it can be assumed that these structures complement the binding pocket(s) for these enzymes. Thus, the resulting models should output a 3-D arrangement of interaction sites predicted to be important for near optimal binding to the CYP2C9 and CYP2C19 enzymes. These predicted interaction regions may then improve the ability to predict drug-drug interactions. The resulting models generated from these new high affinity ligands are discussed, as are novel uses of 3-D QSAR and molecular modeling techniques that may be useful in the study of CYPs specifically.


Key words: computational models, CYP2C, cytochrome P450, inhibition, structure-activity relationships





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.